Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, Enric (Institut d'Investigació Biomèdica Sant Pau)
Pérez Solà, Víctor (Centro de Investigación Biomédica en Red de Salud Mental)
Artigas Pérez, Francesc (Institut d'Investigacions Biomèdiques de Barcelona)
Universitat Autònoma de Barcelona

Date:	2014
Abstract:	Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concentration of serotonin, dopamine, and noradrenaline. Twelve clinical trials have been carried out, nine of which had positive results versus placebo. When active comparators were included in the study design, no significant differences were found except in one study in which the efficacy of vortioxetine was superior to the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors (SSRI)/serotonin-norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies indicate that the drug does not cause any important problems on blood tests, vital signs, or on electrocardiography. The lack of weight gain and induction of metabolic syndrome and the lack of significant changes in the QTc are especially important. The incidence rate of sexual dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains intact with vortioxetine.
Grants:	Instituto de Salud Carlos III SAF 2012-35183
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Depression ; Clinical trial ; Efficacy
Published in:	Neuropsychiatric Disease and Treatment, Vol. 10 (july 2014) , p. 1297-1307, ISSN 1178-2021

DOI: 10.2147/NDT.S41387
PMID: 25075188

11 p, 334.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles